TransMedics Group, Inc. (TMDX) experienced a significant plummet of 8.62% in its stock price during the pre-market session on Monday, January 13th, 2025.
The company issued a statement in response to what they believe are "inaccurate and misleading claims" made in a short-seller report published by Scorpion Capital on January 10th, 2025. TransMedics strongly denied the allegations and stated that the report failed to accurately represent the company's business, technology, diverse culture, and focus on delivering exceptional products and services to the global transplant community.
TransMedics stood by the integrity of its practices, compliance with applicable laws, and commitment to improving clinical outcomes in organ transplantation. The company highlighted that its Organ Care System (OCS) technology and National OCS Program (NOP) have enabled over 7,000 organ transplants, expanded overall U.S. transplant volumes, and delivered exceptional post-transplant clinical outcomes for patients, as validated by their extensive clinical data set.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.